Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Drug

Generate GB-0895 Asthma Phase III Trials to Enroll 1,600 Patients

Fineline Cube Dec 3, 2025

Generate: Biomedicines today announced plans to initiate two global Phase III clinical trials (SOLAIRIA-1 and...

Company Drug

Henlius HLX14 Denosumab Biosimilar NDA Accepted by China CDE

Fineline Cube Dec 3, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the National Medical Products Administration’s Center for...

Company Deals

New-Radiomedicine Series-D Raises 800M Yuan for Radiopharmaceuticals

Fineline Cube Dec 3, 2025

Chengdu New Radiomedicine Technology Co., Ltd. announced completion of its Series D financing round, raising...

Company Deals Drug

Kura ziftomenib Sale Triggers $135M Kyowa-Kirin Payment

Fineline Cube Dec 3, 2025

Kura Oncology, Inc. (NASDAQ: KURA) announced completion of the first US commercial sale of KOMZIFTI...

Company Medical Device

Roche cobas-liat Whooping-Cough Test Secures FDA Clearance

Fineline Cube Dec 3, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its cobas liat system-based point‑of‑care test for whooping...

Company Drug

Henlius HLX37 Bispecific NMPA Approval Targets Advanced Solid Tumors

Fineline Cube Dec 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that its self-developed investigational new drug, HLX37 (Recombinant...

Company Drug

Leads-Biolabs LBL047 Bispecific Secures China IND Approval for SLE

Fineline Cube Dec 2, 2025

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that the National Medical Products Administration (NMPA)...

Company Deals

Shanghai Bao Pharma IPO HKEX Raises HK$1 Billion for Biotech Pipeline

Fineline Cube Dec 2, 2025

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) successfully listed on the Hong Kong Stock Exchange...

Company Drug

Abbisko ABSK141 KRAS-G12D Inhibitor Secures FDA IND Approval

Fineline Cube Dec 2, 2025

Abbisko Cayman Limited (HKG: 2256) announced that its Investigational New Drug (IND) application for ABSK141,...

Company Drug

AbbVie Rinvoq upadacitinib CDE Priority Review Alopecia Areata China

Fineline Cube Dec 2, 2025

AbbVie (NYSE: ABBV) announced that Rinvoq (upadacitinib) has been included in the priority review list...

Company Drug

Lynk Pharma LNK01006 FDA Approval Targets TYK2 for CNS Diseases

Fineline Cube Dec 2, 2025

Lynk Pharmaceuticals Co., Ltd. announced that its self‑developed TYK2 allosteric inhibitor LNK01006 has received FDA...

Others

FDA Prasad Outlines New Vaccine Approval Process After Covid-19 Safety Analysis

Fineline Cube Dec 2, 2025

Dr. Vinay Prasad, FDA’s chief medical and scientific officer, announced plans to overhaul the vaccine...

Hospital Policy / Regulatory

China Health: Life Expectancy Hits 79 Years as Hospitals Expand and Expenditure Controlled

Fineline Cube Dec 2, 2025

The National Health Commission released the Statistical Bulletin on China’s Health Undertakings 2024, showing China’s...

Company Drug

CANbridge’s maralixibat Wins Hong Kong Approval for PFIC Cholestatic Pruritus

Fineline Cube Dec 2, 2025

CANbridge Pharmaceuticals Inc. (HKG: 1228) announced that maralixibat has been approved by the Department of...

Company Deals

WuXi Biologics CRDMO Qatar MOU Establishes First Middle East Center

Fineline Cube Dec 2, 2025

WuXi Biologics (HKG: 2269) announced it has signed a strategic Memorandum of Understanding (MOU) with...

Company Drug

Johnson & Johnson’s Nipocalimab Secures EU Approval for Myasthenia Gravis

Fineline Cube Dec 2, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission has granted Marketing Authorisation...

Company Deals

Regeneron Tessera Partner on TSRA-196 Gene-Writing Therapy for AATD with $275M Deal

Fineline Cube Dec 2, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Tessera Therapeutics announced a global collaboration to develop and...

Company Deals

ChemPartner and Fosun Pharma Forge CRO-CDMO Alliance to Accelerate Drug Development

Fineline Cube Dec 2, 2025

Shanghai ChemPartner Co., Ltd. (SHE: 300149) and Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG:...

Company Medical Device

Microport’s PulseMagic PFA-Catheter Secures NMPA Approval as First Pressure-Monitoring Device in China

Fineline Cube Dec 1, 2025

Shanghai Microport EP Medtech Co., Ltd (SHA: 688351) announced that its PulseMagic TrueForce Disposable Pressure-Monitoring...

Company Drug

Humanwell’s HWS117 Long-Acting FSH Secures NMPA Clinical Trial Approval for Assisted Reproduction

Fineline Cube Dec 1, 2025

Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Class 1 biological product HWS117 injection...

Posts pagination

1 … 16 17 18 … 609

Recent updates

  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
  • NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.